| 摘要: |
| 目的 探讨长链非编码RNA XIST（lncRNA-XIST）在胃癌患者癌组织和血浆中的表达水平及其临床意义。方法 收集2017年2月至7月于第二军医大学长海医院就诊的40例胃癌患者手术切除的胃癌组织及癌旁组织标本，抽取同期90例胃癌患者的术前血浆样本和90例健康体检者血浆样本。利用实时定量PCR（qPCR）检测上述标本中lncRNA-XIST的表达水平。采用非参数检验分析lncRNA-XIST表达水平与胃癌患者临床病理参数（年龄、性别、TNM分期、肿瘤最大径、淋巴结转移、分化程度、Ki-67阳性率）的关系。通过绘制受试者工作特征（ROC）曲线评价lncRNA-XIST在诊断胃癌时的效能。结果 胃癌组织中lncRNA-XIST表达较癌旁组织升高，胃癌患者血浆lncRNA-XIST表达高于健康体检者，差异均有统计学意义[0.150（0.094，0.247）vs 0.085（0.041，0.193）、0.189（0.119，0.256）vs 0.144（0.095，0.180），P均<0.05]。胃癌组织及血浆中的lncRNA-XIST表达水平与胃癌TNM分期、淋巴结转移、分化程度相关（癌组织：Z=3.147、2.729、2.393，血浆：Z=2.769、2.431、2.144；P均<0.05）。血浆lncRNA-XIST诊断胃癌ROC曲线下面积（AUC）为0.753（95%CI：0.681~0.825，P<0.001），截断（cut-off）值为0.197时灵敏度为51.1%、特异度为95.6%；诊断TNMⅠ~Ⅱ期胃癌AUC为0.694（95%CI：0.592~0.796，P<0.01），灵敏度为38.5%，特异度为95.6%；均高于癌胚抗原（CEA）和糖类抗原（CA）19-9、CA72-4单独及联合检测。结论 lncRNA-XIST在胃癌组织及胃癌患者血浆中表达升高，可能是胃癌的一个潜在的肿瘤标志物。 |
| 关键词: 长链非编码RNA lncRNA-XIST 胃肿瘤 血浆 组织 |
| DOI：10.16781/j.0258-879x.2017.11.1403 |
| 投稿时间：2017-09-19修订日期：2017-10-15 |
| 基金项目:国家自然科学基金（81472277）. |
|
| Expression and clinical significance of long non-coding RNA XIST in tissue and plasma of gastric cancer |
| LI Jiang△,SHI Zheng△,LUO Tian-hang,NIE Ming-ming,YUAN Shi-jie,BI Jian-wei* |
(Department of Gastrointestinal Surgery, Changhai Hospital, Second Military Medical University, Shanghai 200433, China
△Co-first authors.
* Corresponding author) |
| Abstract: |
| Objective To investigate the expression levels of long non-coding RNA XIST (lncRNA-XIST) in cancer tissues and plasma of gastric cancer patients and its clinical significance. Methods Resected tumor tissues and adjacent non-tumor tissues of 40 patients with gastric cancer in Changhai Hospital of Second Military Medical University were collected from Feb. to Jul. 2017; the plasma samples were collected from 90 patients with gastric cancer and 90 healthy volunteers. The expression level of lncRNA-XIST in the above samples was detected by real-time quantitative PCR (qPCR).The relationship between the expression level of lncRNA-XIST and the clinicopathological parameters related to gastric cancer (age, gender, TNM stage, tumor maximum diameter, lymph node metastasis, differentiation, and Ki-67 positive rate) were analyzed by nonparametric test. The efficacy of plasma lncRNA-XIST in the diagnosis of gastric cancer was evaluated by plotting the receiver operating characteristic (ROC) curve. Results The expression of lncRNA-XIST in tumor tissues was significantly increased compared with adjacent non-tumor tissues (0.150[0.094, 0.247] vs 0.085[0.041, 0.193], P<0.05), and the lncRNA-XIST expression in plasma in the gastric cancer group was significantly higher than that in the healthy group (0.189[0.119, 0.256] vs 0.144[0.095, 0.180], P<0.05). The expression levels of lncRNA-XIST in plasma and cancer tissues of gastric cancer patients were related to TNM staging, lymph node metastasis and differentiation (cancer tissues:Z=3.147, 2.729 and 2.393; plasma:Z=2.769, 2.431 and 2.144; all P<0.05). Area under ROC curve (AUC) performed by plasmatic lncRNA-XIST for gastric cancer was 0.753 (95%CI 0.681-0.825, P<0.001); when the cut-off value was 0.197, the sensitivity was 51.1% and the specificity was 95.6%. The AUC of diagnosing gastric cancer in TNM Ⅰ-Ⅱ was 0.694(95%CI 0.592-0.796, P<0.01), with a sensitivity of 38.5% a the specificity of 95.6%. All values in above two cases were higher than those of carcino-embryonic antigen (CEA), carbohydrate antigen (CA)19-9, CA72-4 alone or combined detection. Conclusion The expression levels of lncRNA-XIST are increased in cancer tissues and plasma of gastric cancer patients, which may be a potential tumor marker for diagnosing gastric cancer. |
| Key words: long non-coding RNAs lncRNA-XIST stomach neoplasms plasma tissues |
